

68:20.18 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

Canagliflozin

【OCANA】Canaglu® 100 mg/Tab

ATC Code : A10BK02

中文名：可拿糖膜衣錠 «台田»

適應症：第二型糖尿病。

藥理分類：Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.

用法用量：**Administration:**

- Administered with or without food.
- It is recommended to take before the first meal of the day (may reduce postprandial hyperglycemia via delayed intestinal glucose absorption).

Dosage:

Diabetes mellitus, type 2:

Initial: 100 mg QD; may increase to 300 mg once daily.

Renal Impairment

eGFR ≥ 60 mL/minute/1.73 m²: No dosage adjustment necessary.

eGFR 45 to <60 mL/minute/1.73 m²: Maximum dose: 100 mg once daily.

eGFR ≥ 30 to <45 mL/minute/1.73 m²: Not recommended for initiation of therapy or when eGFR is persistently <45 mL/minute/1.73 m².

eGFR <30 mL/minute/1.73 m²: Use is contraindicated.

End-stage renal disease (ESRD): Use is contraindicated.

Hemodialysis: Use is contraindicated.

Safety and efficacy not established in children < 18 yr.

不良反應：低血壓、頻尿、泌尿道感染。

注意事項：1.建議於早餐前或早餐後服用。

2.eGFR 低於 45 mL/min/1.73m²，不建議使用。

3.服用此藥不建議以尿中葡萄糖檢測監測血糖控制。

懷 孕 期：1.懷孕患者應改用胰島素，禁用本品。因安全性尚未建立。

2. Due to adverse effects on renal development observed in animal studies, the manufacturer does not recommend use of canagliflozin during the second and third trimesters of pregnancy.

授 乳 期：1.若使用本品應避免哺乳。

2. It is not known if canagliflozin is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is **not recommended** by the manufacturer.

用藥規定：全民健保—SGLT-2 抑制劑：1.Dapagliflozin (如 Forxiga)、empagliflozin (如 Jardiance)、**canagliflozin (如 Canaglu)**、ertugliflozin (如 Steglatro)--
每日限處方 1 粒。